Fig. 6: Cases demonstrating the predictive value of 68Ga-grazytracer PET for the prognosis of patients after CAR-T cell therapy.
a–d A patient with follicular lymphoma. a The baseline 18F-FDG PET demonstrated intense 18F-FDG-avid mass (SUVmax of 13.9; 12.1 × 8.7 cm in size) in the left abdominal cavity. b 68Ga-grazytracer PET after 1 month of CAR-T cell therapy revealed increased lesion uptake (SUVmax of 5.0). c 18F-FDG PET after 1 month of CAR-T cell therapy showed that the tumor size decreased (7.0 × 3.1 cm vs. 12.1 × 8.7 cm) and SUVmax of 18F-FDG also decreased (SUVmax of 2.2 vs. 13.9) compared with the baseline 18F-FDG PET. d 18F-FDG PET after 14 months of CAR-T cell therapy revealed a complete metabolic response in this patient. e–h A patient with B-cell lymphoma. e The baseline 18F-FDG PET showed a mass with intense 18F-FDG uptake in the left side of the neck (SUVmax of 15.9; 4.1 × 3.4 cm in size). f 68Ga-grazytracer PET after 1 month of CAR-T cell therapy showed no radiotracer uptake in the mass at the left side of the neck. g 18F-FDG PET after 1 month of CAR-T cell therapy revealed that the tumor size decreased (2.8 × 2.4 cm vs. 4.1 × 3.4 cm) and SUVmax of 18F-FDG also decreased (SUVmax of 4.3 vs. 15.9) compared with the baseline 18F-FDG PET. h 18F-FDG PET after 3 months of CAR-T cell therapy revealed overall disease progression in this patient. Arrows indicate tumors in the PET images.
